Skip to main content

Table 1 Clinical characteristics of patients, before and during ezetimibe treatment

From: NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

 

Baseline

6 months

12 months

Body mass index (kg/m2)

23.03 ± 2.04

22.81 ± 2.34

22.84 ± 2.17

ALT (IU/L)

70.13 ± 24.61

36.64 ± 19.41*

34.25 ± 12.61*

GGT (IU/L)

115.00 ± 62.28

69.50 ± 28.49

68.38 ± 28.28

Total cholesterol (mg/dL)

212.00 ± 49.01

192.25 ± 30.68*

191.38 ± 28.61*

Triglyceride (mg/dL)

98.88 ± 34.22

89.88 ± 31.56

94.88 ± 30.62

HDL-cholesterol (mg/dL)

59.13 ± 11.81

58.25 ± 12.09

61.50 ± 12.51

LDL-cholesterol (mg/dL)

137.50 ± 34.59

113.13 ± 29.68*

111.00 ± 29.65*

HOMA-IR

2.31 ± 0.25

2.24 ± 0.14

2.17 ± 0.31

  1. Data are shown as mean ± SD
  2. ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; HOMA-IR, homeostasis model assessment-insulin resistance
  3. *p < 0.05 compared with baseline